Inicio
Annals of the Rheumatic Diseases
|
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (3)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaPOS1106 IMPACT OF LUPUS ACTIVITY AND DAMAGE ACCRUAL ON HOSPITAL-ACQUIRED BACTERIAL INFECTIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / Ruth María Eraso Garnica
Título : POS1106 IMPACT OF LUPUS ACTIVITY AND DAMAGE ACCRUAL ON HOSPITAL-ACQUIRED BACTERIAL INFECTIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Tipo de documento : documento electrónico Autores : Ruth María Eraso Garnica, Autor Fecha de publicación : 2024 Títulos uniformes : Annals of the Rheumatic Diseases Idioma : Inglés (eng) Nota de contenido : Background: Hospital-acquired bacterial infections significantly contribute to the mortality of patients with systemic lupus erythematosus (SLE). The connection between lupus activity, damage accrual, and the risk of nosocomial bacterial infections is not well-established and may be influenced by various confounding factors. Objectives: To assess the impact of disease activity and damage accrual as risk factors for nosocomial bacterial infections in SLE patients. Methods: A retrospective multicenter cohort study was conducted, involving 2217 SLE patients from ten institutions in Colombia. The relationship between lupus activity and organ damage with the occurrence of bacterial infection during hospitalization was evaluated. Lupus activity and damage were assessed using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) scores, respectively. Results were adjusted for confounding variables, including age, sex, chronic renal damage, and the use of glucocorticoids, immunosuppressants, and antimalarials in the preceding month. Logistic regression analyses were performed. Results: The median age was 33 years with an interquartile range (IQR) of 24-46. Eighty-seven percent were women, and 60% had lupus nephritis. The median lupus activity was 8 (IQR 2-13), and cumulative damage was 1 (IQR 0-2). The median length of stay and time to the event were 9 (IQR 6-15) and 8 days (IQR 5-14), respectively. There were 321 outcomes (14.5%). See Table 1. Both SLEDAI and SLICC scores were significantly associated with nosocomial bacterial infection, with unadjusted odds ratios (OR) of 1.05 (95% CI, 1.03-1.07) and 1.24 (95% CI, 1.16-1.32), respectively. OR adjusted for the confounding variables considered were 1.08 (95% CI, 1.06-1.10) for SLEDAI and 1.21 (95% CI, 1.12-1.32) for SLICC. See Table 2. Conclusion: After adjusting for relevant factors, lupus activity and cumulative organ damage were identified as clear risk factors for hospital-acquired bacterial infections in SLE patients. Each one-point increase in SLEDAI and SLICC scores was associated with an 8% and 21% increased risk, respectively. Additionally, our findings suggest a potential protective effect of antimalarials in this clinical context. Mención de responsabilidad : M. Restrepo Escobar, A. L. Vanegas García, R. M. Eraso Garnica, L. Hernandez, C. Muñoz L. A. González, F. Jaimes, G. Vásquez Referencia : Annals of the Rheumatic Diseases 2024;83:949-950. DOI (Digital Object Identifier) : 10.1136/annrheumdis-2024-eular.1039 Derechos de uso : CC BY-NC-ND En línea : https://ard.bmj.com/content/83/Suppl_1/949.2.info Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis POS1106 IMPACT OF LUPUS ACTIVITY AND DAMAGE ACCRUAL ON HOSPITAL-ACQUIRED BACTERIAL INFECTIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS [documento electrónico] / Ruth María Eraso Garnica, Autor . - 2024.
Obra : Annals of the Rheumatic Diseases
Idioma : Inglés (eng)
Nota de contenido : Background: Hospital-acquired bacterial infections significantly contribute to the mortality of patients with systemic lupus erythematosus (SLE). The connection between lupus activity, damage accrual, and the risk of nosocomial bacterial infections is not well-established and may be influenced by various confounding factors. Objectives: To assess the impact of disease activity and damage accrual as risk factors for nosocomial bacterial infections in SLE patients. Methods: A retrospective multicenter cohort study was conducted, involving 2217 SLE patients from ten institutions in Colombia. The relationship between lupus activity and organ damage with the occurrence of bacterial infection during hospitalization was evaluated. Lupus activity and damage were assessed using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) scores, respectively. Results were adjusted for confounding variables, including age, sex, chronic renal damage, and the use of glucocorticoids, immunosuppressants, and antimalarials in the preceding month. Logistic regression analyses were performed. Results: The median age was 33 years with an interquartile range (IQR) of 24-46. Eighty-seven percent were women, and 60% had lupus nephritis. The median lupus activity was 8 (IQR 2-13), and cumulative damage was 1 (IQR 0-2). The median length of stay and time to the event were 9 (IQR 6-15) and 8 days (IQR 5-14), respectively. There were 321 outcomes (14.5%). See Table 1. Both SLEDAI and SLICC scores were significantly associated with nosocomial bacterial infection, with unadjusted odds ratios (OR) of 1.05 (95% CI, 1.03-1.07) and 1.24 (95% CI, 1.16-1.32), respectively. OR adjusted for the confounding variables considered were 1.08 (95% CI, 1.06-1.10) for SLEDAI and 1.21 (95% CI, 1.12-1.32) for SLICC. See Table 2. Conclusion: After adjusting for relevant factors, lupus activity and cumulative organ damage were identified as clear risk factors for hospital-acquired bacterial infections in SLE patients. Each one-point increase in SLEDAI and SLICC scores was associated with an 8% and 21% increased risk, respectively. Additionally, our findings suggest a potential protective effect of antimalarials in this clinical context. Mención de responsabilidad : M. Restrepo Escobar, A. L. Vanegas García, R. M. Eraso Garnica, L. Hernandez, C. Muñoz L. A. González, F. Jaimes, G. Vásquez Referencia : Annals of the Rheumatic Diseases 2024;83:949-950. DOI (Digital Object Identifier) : 10.1136/annrheumdis-2024-eular.1039 Derechos de uso : CC BY-NC-ND En línea : https://ard.bmj.com/content/83/Suppl_1/949.2.info Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002188 AC-2024-041 Archivo digital Producción Científica Artículos científicos Disponible
Título : First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR) Tipo de documento : documento electrónico Autores : Ruth María Eraso Garnica, Fecha de publicación : 2018 Títulos uniformes : Annals of the Rheumatic Diseases Idioma : Inglés (eng) Palabras clave : Lupus nephritis systemic lupus erythematosus treatment Resumen : Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings. Mención de responsabilidad : Bernardo A Pons-Estel, Eloisa Bonfa, Enrique R Soriano, Mario H Cardiel, Ariel Izcovich, Federico Popoff, Juan M Criniti, Gloria Vásquez, Loreto Massardo, Margarita Duarte, Leonor A Barile-Fabris, Mercedes A García, Mary-Carmen Amigo, Graciela Espada, Luis J Catoggio, Emilia Inoue Sato, Roger A Levy, Eduardo M Acevedo Vásquez, Rosa Chacón-Díaz, Claudio M Galarza-Maldonado, Antonio J Iglesias Gamarra, José Fernando Molina, Oscar Neira, Clóvis A Silva, Andrea Vargas Peña, José A Gómez-Puerta, Marina Scolnik, Guillermo J Pons-Estel, Michelle R Ugolini-Lopes, Verónica Savio, Cristina Drenkard, Alejandro J Alvarellos, Manuel F Ugarte-Gil, Alejandra Babini, André Cavalcanti, Fernanda Athayde Cardoso Linhares, Maria Jezabel Haye Salinas, Yurilis J Fuentes-Silva, Ana Carolina Montandon de Oliveira E Silva, Ruth M Eraso Garnica, Sebastián Herrera Uribe, Diana Gómez-Martín, Ricardo Robaina Sevrini, Rosana M Quintana, Sergio Gordon, Hilda Fragoso-Loyo, Violeta Rosario, Verónica Saurit, Simone App Referencia : Ann Rheum Dis. 2018 Nov;77(11):1549-1557. DOI (Digital Object Identifier) : 10.1136/annrheumdis-2018-213512 PMID : 30045853 En línea : https://ard.bmj.com/content/77/11/1549 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR) [documento electrónico] / Ruth María Eraso Garnica, . - 2018.
Obra : Annals of the Rheumatic Diseases
Idioma : Inglés (eng)
Palabras clave : Lupus nephritis systemic lupus erythematosus treatment Resumen : Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings. Mención de responsabilidad : Bernardo A Pons-Estel, Eloisa Bonfa, Enrique R Soriano, Mario H Cardiel, Ariel Izcovich, Federico Popoff, Juan M Criniti, Gloria Vásquez, Loreto Massardo, Margarita Duarte, Leonor A Barile-Fabris, Mercedes A García, Mary-Carmen Amigo, Graciela Espada, Luis J Catoggio, Emilia Inoue Sato, Roger A Levy, Eduardo M Acevedo Vásquez, Rosa Chacón-Díaz, Claudio M Galarza-Maldonado, Antonio J Iglesias Gamarra, José Fernando Molina, Oscar Neira, Clóvis A Silva, Andrea Vargas Peña, José A Gómez-Puerta, Marina Scolnik, Guillermo J Pons-Estel, Michelle R Ugolini-Lopes, Verónica Savio, Cristina Drenkard, Alejandro J Alvarellos, Manuel F Ugarte-Gil, Alejandra Babini, André Cavalcanti, Fernanda Athayde Cardoso Linhares, Maria Jezabel Haye Salinas, Yurilis J Fuentes-Silva, Ana Carolina Montandon de Oliveira E Silva, Ruth M Eraso Garnica, Sebastián Herrera Uribe, Diana Gómez-Martín, Ricardo Robaina Sevrini, Rosana M Quintana, Sergio Gordon, Hilda Fragoso-Loyo, Violeta Rosario, Verónica Saurit, Simone App Referencia : Ann Rheum Dis. 2018 Nov;77(11):1549-1557. DOI (Digital Object Identifier) : 10.1136/annrheumdis-2018-213512 PMID : 30045853 En línea : https://ard.bmj.com/content/77/11/1549 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000792 AC-2018-079 Archivo digital Producción Científica Artículos científicos Disponible
Título : TAP1 and TAP2 polymorphisms analysis in northwestern Colombian patients with systemic lupus erythematosus Tipo de documento : documento electrónico Autores : José Fernando Molina Restrepo, Fecha de publicación : 2003 Títulos uniformes : Annals of the Rheumatic Diseases Idioma : Inglés (eng) Resumen : Objective: To determine the influence of TAP1 and TAP2 alleles in northwestern Colombian patients with systemic lupus erythematosus (SLE). Methods: Unselected patients with SLE (n=140) and controls (n=120) matched for sex, age, and ethnicity were analysed. Clinical manifestations, clinical activity, and severity of disease were recorded. Autoantibodies were detected by enzyme linked immunosorbent assay (ELISA). TAP1 and TAP2 polymorphisms were determined by amplification refractory mutation system-polymerase chain reaction. A Hardy-Weinberg equilibrium test, microdifferentiation analysis, linkage disequilibrium analysis, and haplotype and allele frequency comparisons were performed. Results: The TAP2 variant Val379/Ala565/Ala665 (allele TAP2*0201) was associated with SLE (56% v 39%; odds ratio=2, 95% confidence interval 1.22 to 3.30, pc=0.03). There was no stratification between patient and control samples. Linkage disequilibrium between TAP1 and TAP2 loci was found in controls but not in patients. An excess in the number of heterozygotes in the TAP2 locus was found in patients. No association between TAP1 and TAP2 variants and the presence of autoantibodies, clinical expression, or severity of disease was found. Conclusions: The TAP2 locus influences susceptibility to SLE in our patient group; however, it has no significant effect on the immune response or on the clinical course of the disease. Mención de responsabilidad : P A Correa, J F Molina, L F Pinto, M Arcos-Burgos, M Herrera, J-M Anaya Referencia : Ann Rheum Dis. 2003 Apr;62(4):363-5. DOI (Digital Object Identifier) : 10.1136/ard.62.4.363 PMID : 12634240 En línea : https://ard.bmj.com/content/62/4/363 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis TAP1 and TAP2 polymorphisms analysis in northwestern Colombian patients with systemic lupus erythematosus [documento electrónico] / José Fernando Molina Restrepo, . - 2003.
Obra : Annals of the Rheumatic Diseases
Idioma : Inglés (eng)
Resumen : Objective: To determine the influence of TAP1 and TAP2 alleles in northwestern Colombian patients with systemic lupus erythematosus (SLE). Methods: Unselected patients with SLE (n=140) and controls (n=120) matched for sex, age, and ethnicity were analysed. Clinical manifestations, clinical activity, and severity of disease were recorded. Autoantibodies were detected by enzyme linked immunosorbent assay (ELISA). TAP1 and TAP2 polymorphisms were determined by amplification refractory mutation system-polymerase chain reaction. A Hardy-Weinberg equilibrium test, microdifferentiation analysis, linkage disequilibrium analysis, and haplotype and allele frequency comparisons were performed. Results: The TAP2 variant Val379/Ala565/Ala665 (allele TAP2*0201) was associated with SLE (56% v 39%; odds ratio=2, 95% confidence interval 1.22 to 3.30, pc=0.03). There was no stratification between patient and control samples. Linkage disequilibrium between TAP1 and TAP2 loci was found in controls but not in patients. An excess in the number of heterozygotes in the TAP2 locus was found in patients. No association between TAP1 and TAP2 variants and the presence of autoantibodies, clinical expression, or severity of disease was found. Conclusions: The TAP2 locus influences susceptibility to SLE in our patient group; however, it has no significant effect on the immune response or on the clinical course of the disease. Mención de responsabilidad : P A Correa, J F Molina, L F Pinto, M Arcos-Burgos, M Herrera, J-M Anaya Referencia : Ann Rheum Dis. 2003 Apr;62(4):363-5. DOI (Digital Object Identifier) : 10.1136/ard.62.4.363 PMID : 12634240 En línea : https://ard.bmj.com/content/62/4/363 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000897 AC-2003-004 Archivo digital Producción Científica Artículos científicos Disponible
